Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024
Edgewise Therapeutics (Nasdaq: EWTX), a muscle disease biopharmaceutical company, has announced its upcoming participation at the Piper Sandler 36th Annual Healthcare Conference. The presentation is scheduled for Tuesday, December 3, 2024, at 1 pm ET.
The event will feature a live webcast accessible through the company's Events & Presentations page. Viewers are advised to connect several minutes before the start time to ensure proper connection. The webcast recording will be available for replay for a period after the conference.
Edgewise Therapeutics (Nasdaq: EWTX), una società biofarmaceutica specializzata nelle malattie muscolari, ha annunciato la sua prossima partecipazione alla 36ª Conferenza Annuale sulla Salute di Piper Sandler. La presentazione è fissata per martedì 3 dicembre 2024, alle 13:00 ET.
L'evento includerà una trasmissione in diretta accessibile tramite la pagina Eventi e Presentazioni della società. Si consiglia agli spettatori di connettersi alcuni minuti prima dell'orario di inizio per garantire una connessione adeguata. La registrazione della trasmissione sarà disponibile per la visione per un periodo di tempo dopo la conferenza.
Edgewise Therapeutics (Nasdaq: EWTX), una empresa biofarmacéutica dedicada a las enfermedades musculares, ha anunciado su próxima participación en la 36ª Conferencia Anual de Salud de Piper Sandler. La presentación está programada para el martes 3 de diciembre de 2024, a la 1:00 pm ET.
El evento contará con una transmisión en vivo accesible a través de la página de Eventos y Presentaciones de la compañía. Se aconseja a los espectadores conectarse varios minutos antes de la hora de inicio para asegurar una conexión adecuada. La grabación de la transmisión estará disponible para su reproducción por un periodo de tiempo después de la conferencia.
엣지와이즈 테라퓨틱스 (Nasdaq: EWTX), 근육 질환을 전문으로 하는 생명공학 제약 회사,가 파이퍼 샌들러 제36회 연례 헬스케어 컨퍼런스에 참여할 예정이라고 발표했습니다. 발표는 2024년 12월 3일 화요일, 동부 표준시 기준 오후 1시에 예정되어 있습니다.
본 행사에서는 회사의 이벤트 및 프레젠테이션 페이지를 통해 접속 가능한 라이브 웹캐스트가 진행됩니다. 관람객은 적절한 연결을 보장하기 위해 시작 시간 몇 분 전에는 접속할 것을 권장합니다. 웹캐스트 녹음은 컨퍼런스 후 일정 기간 동안 재생 가능합니다.
Edgewise Therapeutics (Nasdaq: EWTX), une société biopharmaceutique spécialisée dans les maladies musculaires, a annoncé sa prochaine participation à la 36e Conférence Annuelle de Santé Piper Sandler. La présentation est prévue pour le mardi 3 décembre 2024, à 13h00 ET.
L'événement comportera un webinaire en direct accessible via la page Événements et Présentations de la société. Il est conseillé aux spectateurs de se connecter plusieurs minutes avant l'heure de début pour garantir une bonne connexion. L'enregistrement du webinaire sera disponible en replay pendant une période après la conférence.
Edgewise Therapeutics (Nasdaq: EWTX), ein biopharmazeutisches Unternehmen, das auf Muskelkrankheiten spezialisiert ist, hat seine kommende Teilnahme an der 36. jährlichen Gesundheitskonferenz von Piper Sandler angekündigt. Die Präsentation ist für Dienstag, den 3. Dezember 2024, um 13 Uhr ET geplant.
Die Veranstaltung wird einen Live-Stream beinhalten, der über die Seite für Veranstaltungen und Präsentationen des Unternehmens zugänglich ist. Zuschauern wird geraten, sich mehrere Minuten vor Beginn der Veranstaltung zu verbinden, um eine ordnungsgemäße Verbindung sicherzustellen. Die Aufzeichnung des Streams wird für einen Zeitraum nach der Konferenz zur Verfügung stehen.
- None.
- None.
The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, X , Facebook and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241126273809/en/
Edgewise Contacts
Investors:
Michael Carruthers, Chief Financial Officer
ir@edgewisetx.com
Media:
Maureen Franco, VP Corporate Communications
media@edgewisetx.com
Source: Edgewise Therapeutics
FAQ
When is Edgewise Therapeutics (EWTX) presenting at the Piper Sandler Healthcare Conference 2024?
How can I watch Edgewise Therapeutics' (EWTX) presentation at the Piper Sandler Conference?
Will there be a replay available of Edgewise Therapeutics' (EWTX) Piper Sandler Conference presentation?
